Metabolic Optimization · Reviewed by Ian K. Tseng, MD

What Is Tirzepatide? The Dual GIP and GLP-1 Mechanism

Tirzepatide is often described as being in the same family as semaglutide, which is true but incomplete. It acts on two receptors rather than one, and that second target — GIP — is the reason it is classified as a first-in-class molecule rather than another entry in an existing category. Here is what the dual mechanism means.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Soothe IV Med Spa branded amber pharmacy vial on warm marble, representing the metabolic optimization category of physician-supervised peptide therapy

The short answer

Tirzepatide is a 39-amino-acid synthetic peptide that activates two incretin receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most incretin therapies target GLP-1 alone. Adding GIP receptor agonism engages a second, parallel arm of the body's post-meal signaling system. Like semaglutide, it is engineered for resistance to rapid enzymatic breakdown and is dosed once weekly.

Two incretins, not one

Your gut releases more than one incretin hormone after a meal. GLP-1 is the better known. GIP — glucose-dependent insulinotropic polypeptide — is actually the more abundant of the two and was identified earlier, but it received less therapeutic attention for decades because its insulin-releasing effect appeared blunted in the context of type 2 diabetes.

Tirzepatide activates both receptors with a single molecule. The working hypothesis in the literature is that GIP receptor agonism contributes effects that GLP-1 agonism alone does not fully reproduce, including effects on adipose tissue metabolism and possibly on the tolerability of the GLP-1 component. Research is ongoing and mechanistic understanding continues to develop.

Structurally, tirzepatide is based on the native GIP sequence with modifications that give it activity at the GLP-1 receptor as well, plus a fatty-acid chain enabling albumin binding — the same half-life-extension strategy used in semaglutide. The result supports once-weekly administration.

What this changes clinically, and what it does not

The dual mechanism does not change the fundamentals of responsible prescribing. Tirzepatide is still titrated slowly from a low starting dose. It still produces predominantly gastrointestinal side effects that are most pronounced during escalation. It still requires baseline bloodwork and ongoing monitoring, and it still carries the same class considerations regarding thyroid C-cell findings in rodent studies, with the same contraindication for personal or family history of medullary thyroid carcinoma or MEN2.

What it does change is that a physician now has two mechanistically distinct options within the same category of care, and the choice between them is individualized. That decision is made during clinical evaluation based on your history, labs, and goals — not selected from a menu.

Side effects and monitoring

Reported adverse effects are dominated by the gastrointestinal tract: nausea, diarrhea, vomiting, constipation, and reduced appetite. As with any incretin therapy, these track dose escalation. Persistent vomiting raises dehydration and kidney-function concerns, which is one reason follow-up contact during titration is built into a managed protocol rather than left to the patient to initiate.

Additional considerations a physician screens for include pancreatitis history, gallbladder disease, gastrointestinal motility disorders, diabetic retinopathy status, and concurrent glucose-lowering medications that could compound hypoglycemia risk.

Bloodwork comes first

The baseline panel for a metabolic protocol generally covers hemoglobin A1c, fasting glucose and insulin, comprehensive metabolic panel, lipids, and thyroid function. These establish appropriateness, surface contraindications, and create the comparison baseline for follow-up testing. Our bloodwork explainer details what each marker is used for.

If you have had a relevant panel drawn in the last twelve months, those results can often be used rather than repeating the draw — one of the questions the intake form asks.

Frequently asked questions

What is the difference between tirzepatide and a GLP-1-only medication?

Tirzepatide activates two incretin receptors — GIP and GLP-1 — with a single molecule, while most incretin therapies target GLP-1 alone. GIP is the more abundant of the two gut incretin hormones. The literature suggests GIP receptor agonism contributes effects on adipose tissue metabolism and possibly on tolerability that GLP-1 agonism alone does not fully reproduce, though mechanistic understanding continues to develop.

How is tirzepatide dosed?

Once weekly, following a titration schedule that starts at a low dose and escalates over weeks. A fatty-acid chain enabling albumin binding extends the half-life to support weekly administration. The escalation schedule is set and adjusted by the prescribing physician based on individual tolerance.

What are the most common side effects?

Predominantly gastrointestinal: nausea, diarrhea, vomiting, constipation, and reduced appetite. These are dose-dependent and most pronounced during dose escalation. Persistent vomiting is clinically relevant because of dehydration and kidney-function risk, which is why managed protocols include scheduled follow-up during titration.

Does tirzepatide require bloodwork?

Yes. A baseline panel typically covering hemoglobin A1c, fasting glucose and insulin, comprehensive metabolic panel, lipids, and thyroid function is reviewed before any prescription, and repeated periodically during therapy. Results from a relevant panel drawn in the last twelve months can often be used instead of a new draw.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism. 2018. pmc.ncbi.nlm.nih.gov
Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes. Cardiovascular Diabetology. 2022. pmc.ncbi.nlm.nih.gov
U.S. Food & Drug Administration. Human Drug Compounding. www.fda.gov

Ready to talk to a physician?

Start your $50 Application — the comprehensive intake, physician Good Faith Examination, and medical clearance. A physician reviews your goals and labs and tells you honestly whether therapy is appropriate. Your fee credits in full toward your first month of membership. Available nationwide.

Book & Pay for Your $50 Application

Serving Orange County, Los Angeles, and San Diego — plus nationwide telehealth. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.